血清白细胞介素-8(IL-8)水平变化可反映并预测黑色素瘤及非小细胞肺癌患者对抗PD-1治疗的应答
研究纳入接受纳武利尤单抗或帕博利珠单抗单药或纳武利尤单抗联合伊匹木单抗治疗的转移性黑色素瘤及非小细胞肺癌患者,采用夹心ELISA法检测基线和治疗早期血清IL-8水平。结果示应答者血清IL-8从基线至最佳应答显著下降,进展时显著升高;非应答者从基线至进展显著升高;早期IL-8下降与黑色素瘤和非小细胞肺癌患者更长的总生存相关。
要点
- 黑色素瘤应答者血清IL-8从基线至最佳应答显著下降(P<0.001),进展时显著升高(P=0.004)。
- 非应答者血清IL-8从基线至进展显著升高(P=0.013)。
- 治疗开始后2-4周早期IL-8变化与应答强烈相关(黑色素瘤P<0.001,非小细胞肺癌P=0.001)。
核心结论
- 血清IL-8水平变化可用于监测和预测黑色素瘤及非小细胞肺癌患者免疫检查点阻断治疗的临床获益。
研究设计与样本
- 研究纳入接受纳武利尤单抗或帕博利珠单抗单药或纳武利尤单抗联合伊匹木单抗治疗的转移性黑色素瘤和非小细胞肺癌患者。
- 在基线、首次给药后2-4周及应答评估时点采集血清,采用夹心ELISA法测定IL-8水平。
主要发现
- 29例接受纳武利尤单抗或帕博利珠单抗治疗的黑色素瘤患者中,应答者血清IL-8从基线至最佳应答显著下降(P<0.001),进展时显著升高(P=0.004);非应答者从基线至进展显著升高(P=0.013)。
- 治疗开始后2-4周早期血清IL-8变化与应答强烈相关(P<0.001),并在19例接受纳武利尤单抗或帕博利珠单抗治疗的非小细胞肺癌患者(P=0.001)及15例接受纳武利尤单抗联合伊匹木单抗治疗的黑色素瘤患者(P<0.001)中得到验证。
- 早期血清IL-8下降与黑色素瘤(P=0.001)和非小细胞肺癌(P=0.015)患者更长的总生存相关。
- 血清IL-8水平在三例出现假性进展的癌症患者中正确反映了真实应答。
关键数值与推荐
- 应答者血清IL-8从基线至最佳应答显著下降(P<0.001),进展时显著升高(P=0.004)。
- 非应答者血清IL-8从基线至进展显著升高(P=0.013)。
- 早期(治疗开始后2-4周)血清IL-8变化与应答相关:黑色素瘤P<0.001,非小细胞肺癌P=0.001,纳武利尤单抗联合伊匹木单抗治疗的黑色素瘤P<0.001。
- 早期血清IL-8下降与总生存相关:黑色素瘤P=0.001,非小细胞肺癌P=0.015。
临床怎么用
- 原文结论指出血清IL-8水平变化可用于监测和预测黑色素瘤及非小细胞肺癌患者免疫检查点阻断治疗的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of changes in IL-8 levels to predict response was estimated using receiver operation characteristics curves. RESULTS: Twenty-nine melanoma patients treated with nivolumab or pembrolizumab were studied. In responding patients, serum IL-8 levels significantly decreased between baseline and best response (P <0.001), and significantly increased upon progression (P = 0.004). In non-responders, IL-8 levels significantly increased between baseline and progression (P = 0.013). Early changes in serum IL-8 levels (2-4 weeks after treatment initiation) were strongly associated with response (P <0.001). These observations were validated in 19 NSCLC patients treated with nivolumab or pembrolizumab (P = 0.001), and in 15 melanoma patients treated with nivolumab plus ipilimumab (P <0.001). Early decreases in serum IL-8 levels were associated with longer overall survival in melanoma (P = 0.001) and NSCLC (P = 0.015) patients. Serum IL-8 levels also correctly reflected true response in three cancer patients presenting pseudoprogression. CONCLUSIONS: Changes in serum IL-8 levels could be used to monitor and predict clinical benefit from immune checkpoint blockade in melanoma and NSCLC patients.
引用
- Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017. PMID: 28595336. doi:10.1093/annonc/mdx190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。